Related Experiment Video
Updated: Feb 9, 2026
04:51
Pupillary Response as Assessment of Effective Seizure Induction by Electroconvulsive Therapy
Published on: April 11, 2019
10.5K
egl-4 modulates electroconvulsive seizure duration in C. elegans.
Monica G Risley1,2, Stephanie P Kelly1,2, Justin Minnerly1,2
1Department of Biological Sciences, Florida Atlantic University, Boca Raton, FL, 33431, USA.
Invertebrate Neuroscience : IN
|May 31, 2018
Summary
This study shows that activating the protein kinase G (PKG) pathway reduces seizure duration in C. elegans. This finding suggests a new therapeutic target for controlling seizures and epilepsy.
Area of Science:
- Neuroscience
- Pharmacology
- Genetics
Background:
- Neuronal excitability underlies seizures, a condition with limited effective treatments due to its complexity.
- The cGMP/protein kinase G (PKG) pathway represents a novel therapeutic target for seizure control.
- PKG influences K+ channels, a mechanism shared with the antiepileptic drug Retigabine.
Purpose of the Study:
- To investigate the role of the PKG pathway in modulating seizure duration.
- To evaluate the efficacy of PKG activators and Retigabine in a C. elegans seizure model.
- To establish C. elegans as a viable model for high-throughput screening of anti-seizure compounds.
Main Methods:
- Development and utilization of a novel electroconvulsive seizure assay in C. elegans.
- Treatment of C. elegans with Retigabine and pharmaceuticals known to increase PKG activity.
- Measurement of seizure recovery times following treatment.
Main Results:
- Increased PKG activity significantly decreased seizure duration in C. elegans.
- Pharmacological activation of PKG and treatment with Retigabine reduced seizure recovery times.
- C. elegans demonstrated drug uptake and responsiveness suitable for high-throughput screening.
Conclusions:
- PKG signaling modulates K+ channel conductance, controlling seizure recovery time in C. elegans.
- Pharmacological targeting of the PKG pathway offers a promising strategy for seizure control.
- C. elegans serves as an effective model for discovering novel anti-epileptic therapeutics.
More Related Videos
Related Concept Videos
01:30Electroconvulsive Therapy
1.2K
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
1.2K
01:13Seizures: Classification
1.7K
Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
1.7K
01:24Epilepsy and Seizures: Overview
1.4K
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.4K
01:23Dipeptidyl Peptidase 4 Inhibitors
687
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
687
01:19Piaget's Stage 4 of Cognitive Development
678
The formal operational stage, as described in Piaget's cognitive development theory, begins around age 11 and extends into adulthood. It marks the emergence of advanced cognitive abilities that differentiate adolescent and adult thinking from those of younger children. This stage is characterized by abstract reasoning, hypothetical-deductive reasoning, and a more complex understanding of self and others.
Abstract Reasoning and Hypothetical-Deductive Thinking
Unlike the concrete operational...
Abstract Reasoning and Hypothetical-Deductive Thinking
Unlike the concrete operational...
678
01:20Amides to Amines: LiAlH4 Reduction
6.3K
Amide reduction with strong reducing agents like lithium aluminum hydride proceeds through a nucleophilic acyl substitution to form amines. Primary, secondary, and tertiary amides yield primary, secondary, and tertiary amines, respectively.
Amide reduction requires two equivalents of the reducing agent, acting as a source of hydride ions. As shown in the figure, the reaction is initiated with a nucleophilic attack by the hydride ion at the carbonyl carbon to form a tetrahedral intermediate.
Amide reduction requires two equivalents of the reducing agent, acting as a source of hydride ions. As shown in the figure, the reaction is initiated with a nucleophilic attack by the hydride ion at the carbonyl carbon to form a tetrahedral intermediate.
6.3K